BioCubaFarma: an organization of excellence for the future of humanity

Production facilities in BioCubaFarma company

BioCubaFarma, a corporation of the Biotechnology and Pharmaceutical Company of Cuba, produces medicines, equipment and services high technology for the improvement of human health, and facilitates the production of exportable goods and services and the production of food with its advanced technology.

Developed on a sound scientific basis and high quality standards, its strength and added value derives from its 46 companies, 115 production lines, 20 science and technology units and the more than 19,000 workers. Its highly professional workforce includes 258 doctorates and 1,265 members of staff with master's degrees dedicated to research and development.

With more than 40 years of research experience, fulfilling Good Manufacturing Practices, clinical trials and exports, the Cuban biopharmaceutical industry is now a mature sector. Among its main products are prophylactic vaccines for infectious diseases; biopharmaceuticals for the treatment of cancer, such as monoclonal antibodies and therapeutic vaccines; and products for the prevention and treatment of cardiovascular diseases as well as diabetic foot ulcers. Products also manufactured include new generation generics and pharmaceutical compounds, and systems for the early diagnosis and prevention of malignant tumours, malformations and more.

In addition, they develop and produce products of natural origin, blood products, advanced medical equipment, nanotechnology, neuroscience and neurotechnology products and other agricultural equipment.

Production facilities in BioCubaFarma company

In its portfolio of BioCubaFarma projects, it currently has more than 390 projects at different stages of development. These projects include those related to oncological diseases, infectious diseases, neurodegenerative, autoimmune, cardiovascular diseases and the application of biomedical and agricultural research. The industry has a wide portfolio of investments with 2,640 patents registered in Cuba and abroad.

This corporation manufactures and distributes more than 1,000 products, including 795 that are supplied to the Basic Table of Medicines of Cuba.

These have a high impact on the health of the population and satisfy different health programmes covering all stages of life.

Among its innovative products you will find Heberprot-P ®, the CIMAvax-EGF, CIMAher, Jusvinza, Nasalferon, BiomodulinT, Itolizumab, NeuralCim, PPG, Melagenin Plus, Proctokinase ®, HeberNasvac ®, the Cuban vaccines against covid19; Abdala, Soberana 02 and Soberana Plus, among others.

BioCubaFarma, has a wide international presence, through 8 joint ventures. Six of which are in different countries including China, Spain and Singapore, with 2 joint ventures in Cuba. It also has 6, 100% Cuban companies in countries such as Venezuela, Ecuador and Brazil, a representative office in China and a branch in Colombia. Scientific collaboration, research centres, as well as its export of products to more than 50 countries and the 769 health records in Cuba and abroad, consolidate its international presence.

Currently, the Cuban biopharmaceutical industry is ready to grow. Its portfolio of products and intangible assets provides the basis for an open and flexible collaboration with external partners through different business models including:

1. The negotiation of projects at early stages of development.

2. The licensing and co-development of projects, creation of joint ventures in Cuba and abroad.

3. Representation and distribution contracts, business creation 100% Cuban capital abroad.

4. Contracts for technology transfer and manufacturing services.

Its innovative capacity and contributions to health are just some of the advantages of BioCubaFarma and make it an organization of excellence for the future of humanity.

Contact:

contacto@oc.biocubafarma.cu

www.biocubafarma.cu